Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer

Mazzoni, Francesca; Cecere, Fabiana Letizia; Meoni, Giulia; Giuliani, Costanza; Boni, Luca; Camerini, Andrea; Lucchesi, Sara; Martella, Francesca; Amoroso, Domenico; Lucherini, Elisa; Torricelli, Francesca; Costanzo, Francesco Di

doi:10.1016/j.lungcan.2013.08.018

Cited by 32 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polymorphisms in genes encoding carboplatin-or paclitaxel-metabolizing enzymes and transporters, and those in genes encoding DNA repair proteins may be part of such factors. Many pharmacogenetic studies have been previously conducted for these drugs focusing on polymorphisms in ABCB1, CYP3A4, CYP1B1, CYP2C8 genes as well as in NQO1 and DNA repair genes, and conflicting results were obtained [22][23][24][25][26][27][28]. In the present study, no association between patients' sensitivity to hematotoxicity and polymorphisms of these genes was found.…”

Section: Discussioncontrasting

confidence: 62%

Polymorphisms in Slco1B3 and Nr1I2 as Genetic Determinants of Hematotoxicity of Carboplatin and Paclitaxel Combination

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 62%

Polymorphisms in Slco1B3 and Nr1I2 as Genetic Determinants of Hematotoxicity of Carboplatin and Paclitaxel Combination

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Previous reports suggested that elevated ERCC1 expression is associated with poor response to chemotherapy; nevertheless, in the current study, it was observed that ERCC1-C8092 was associated with low ERCC1 mRNA levels. In a recent phase II study, treatment was administered based on ERCC1 SNPs, assuming that patients with the A allele in ERCC1 would not respond to platinum-based chemotherapy; in spite of improvement in ORR, this benefit did not translate to PFS and OS gain (32). In prostate cancer, Woelfelschneider et al (33) have shown that lower ERCC1 mRNA levels in primary lymphocytes associated with the CC haplotype of ERCC1-C8092A and Asn118Asn SNPs.…”

Section: Discussionmentioning

confidence: 99%

ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Kalikaki

Voutsina

Koutsopoulos³

et al. 2015

Cancer Investigation

View full text Add to dashboard Cite

Polymorphisms in ERCC1, XPD, and XRCC1 were examined for (a) association with the clinical outcome of 107 non-small cell lung cancer patients receiving front-line platinum-based chemotherapy, and (b) correlation with the ERCC1 mRNA levels of 176 chemo-naive primary tumors. The ERCC1-C8092 allele and the number of ERCC1 polymorphic variants (C8092A and Asn118Asn) were associated with progression-free survival. In non-squamous histology, tumoral ERCC1 mRNA levels were lower in patients homozygous for ERCC1-C8092 as compared with the patients carrying the A allele (p = .024). These findings merit investigation in larger cohorts of patients treated with uniform regimens.

show abstract

“…For rs3212986, several previous studies indicated that the ERCC1 rs3212986 polymorphism could be used as a prognostic factor in platinum-based treatment of NSCLC (Takenaka et al, 2010;Mazzoni et al, 2013). Two previous studies conducted in Japan indicated that the ERCC1 rs3212986 CA genotype was significantly associated with poorer disease-free survival and overall survival compared to those with the CC genotype in NSCLC patients treated with platinum-based chemotherapy (Takenaka et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

Gao¹,

Ge²,

Liu³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair crosscomplementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were followed up until December 2012. ERCC1 rs11615, rs3212986, and rs2298881 were selected and genotyped. Of the 163 patients, 86 patients showed a complete response and partial response to chemotherapy (52.76%), while 91 patients (55.83%) died from NSCLC during the follow-up period with a median survival time of 19.3 months (range, 2-60 months). Multivariate regression analysis showed that individuals carrying the rs11615 TT genotype and T allele had a significantly lower response rate to chemotherapy using the rs11615 CC genotype as the reference. For rs3212986, carriers of the rs3212986 AA genotype and A allele had a significantly lower response rate to chemotherapy when compared with the CC genotype. In the Cox proportional hazards model, patients carrying the rs11615 TT genotype and T allele and the rs3212986 AA genotype and A allele were significantly associated with increased risk of death from NSCLC. We found that polymorphisms in ERCC1 rs11615 and rs3212986 were associated with poor response to chemotherapy and shorter survival time of advanced NSCLC.

show abstract

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer

Cited by 32 publications

References 28 publications

Polymorphisms in Slco1B3 and Nr1I2 as Genetic Determinants of Hematotoxicity of Carboplatin and Paclitaxel Combination

Polymorphisms in Slco1B3 and Nr1I2 as Genetic Determinants of Hematotoxicity of Carboplatin and Paclitaxel Combination

ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

Contact Info

Product

Resources

About